Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Eses Holdings (fze) and Adamis Pharmaceuticals Corp (ADMP)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Eses Holdings (FZE) 0 1,635,312 0 1,635,312 1,635,312 5.9%
Ahmed Shayan Fazlur Rahman 0 1,635,312 0 1,635,312 1,635,312 5.9%

Page 1 of 9 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE
13D

Under the Securities Exchange Act of 1934

(Amendment No. 11)*

ADAMIS
PHARMACEUTICALS CORPORATION

Name of Issuer

COMMON
STOCK, $0.0001 Par Value

(Title of Class of Securities)

00547W208

(CUSIP Number)

Ahmed Shayan Fazlur Rahman

c/o Eses Holdings (FZE)

Sharjah Airport International Free Zone

Executive Suite, P.O. Box 9366

Sharjah, United Arab Emirates
+971-4-363-846

(Name,
Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

April 26, 2017

(Date of Event which Requires Filing of
this Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§
240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies
are to be sent.

* The information required on the
remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).

Follow Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
Trade (NASDAQ:ADMP) Now!
Loading...